American Cancer Society. Cancer Facts & Figures 2022. Atlanta: American Cancer Society; 2022.

Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer: a gynecologic oncology group study. Cancer. 1987;60(S8):2035–41. https://doi.org/10.1002/1097-0142(19901015)60:8+%3c2035::AID-CNCR2820601515%3e3.0.CO;2-8.

Article  CAS  PubMed  Google Scholar 

Hoekstra AV, Kim RJ, Small W, et al. FIGO stage IIIC endometrial carcinoma: prognostic factors and outcomes. Gynecol Oncol. 2009;114(2):273–8. https://doi.org/10.1016/j.ygyno.2009.04.013.

Article  PubMed  Google Scholar 

Devita VT Jr, Wasserman TH, Young RC, Carter SK. Perspectives on research in gynecologic oncology. Treatment protocols Cancer. 1976;38(1):509–25. https://doi.org/10.1002/1097-0142(197607)38:1%3c509::AID-CNCR2820380175%3e3.0.CO;2-A.

Article  Google Scholar 

Muggia FM, Chia G, Reed LJ, Romney SL. Doxorubicin-cyclophosphamide: effective chemotherapy for advanced endometrial adenocarcinoma. Am J Obstet Gynecol. 1977;128(3):314–9. https://doi.org/10.1016/0002-9378(77)90629-9.

Article  CAS  PubMed  Google Scholar 

Burke TW, Stringer CA, Morris M, Freedman RS, Gershenson DM, Kavanagh JJ, Edwards CL. Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide. Gynecol Oncol. 1991;40(3):264–7. https://doi.org/10.1016/0090-8258(90)90289-w.

Barrett RJ, Blessing JA, Homesley HD, Twiggs L, Webster KD. Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. A phase II study of the Gynecologic Oncology Group. Am J Clin Oncol. 1993;16(6):494–6. https://doi.org/10.1097/00000421-199312000-00007.

Article  CAS  PubMed  Google Scholar 

Thigpen JT, Brady MF, Homesley HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2004;22(19):3902–8. https://doi.org/10.1200/JCO.2004.02.088.

Article  CAS  PubMed  Google Scholar 

Ball HG, Blessing JA, Lentz SS, Mutch DG. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1996;62(2):278–81. https://doi.org/10.1006/gyno.1996.0227.

Article  CAS  PubMed  Google Scholar 

Fleming GF, Filiaci VL, Bentley RC, et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol. 2004;15(8):1173–8. https://doi.org/10.1093/annonc/mdh316.

Article  CAS  PubMed  Google Scholar 

Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2004;22(11):2159–66. https://doi.org/10.1200/JCO.2004.07.184.

Article  CAS  PubMed  Google Scholar 

Sovak MA, Hensley ML, Dupont J, et al. Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study. Gynecol Oncol. 2006;103(2):451–7. https://doi.org/10.1016/j.ygyno.2006.03.019.

Article  CAS  PubMed  Google Scholar 

Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209). J Clin Oncol. 2020;38(33):3841–50. https://doi.org/10.1200/JCO.20.01076.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haunschild CE, Tewari KS. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer. Future Oncol. 2020;16(7):225–46. https://doi.org/10.2217/fon-2019-0042.

Article  CAS  PubMed  Google Scholar 

Lorusso D, Ferrandina G, Colombo N, et al. Carboplatin-paclitaxel compared to carboplatin-paclitaxel-bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - a randomized phase II trial. Gynecol Oncol. 2019;155(3):406–12. https://doi.org/10.1016/j.ygyno.2019.10.013.

Article  CAS  PubMed  Google Scholar 

Aghajanian C, Filiaci V, Dizon DS, et al. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol. 2018;150(2):274–81. https://doi.org/10.1016/j.ygyno.2018.05.018.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2006;24(1):36–44. https://doi.org/10.1200/JCO.2004.00.7617.

Article  CAS  PubMed  Google Scholar 

Maggi R, Lissoni A, Spina F, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer. 2006;95(3):266–71. https://doi.org/10.1038/sj.bjc.6603279.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Susumu N, Sagae S, Udagawa Y, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol. 2008;108(1):226–33. https://doi.org/10.1016/j.ygyno.2007.09.029.

Article  CAS  PubMed  Google Scholar 

•de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(3):295–309. https://doi.org/10.1016/S1470-2045(18)30079-2. (Trial comparing RT in high-risk EC as a control group to RT with the addition of cytotoxic chemotherapy, demonstrating no overall survival benefit in the experimental group but with a PFS benefit.)

•de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2019;20(9):1273–1285. https://doi.org/10.1016/S1470-2045(19)30395-X. (A subset analysis of PORTEC-3 which shows a possible survival benefit of adding chemotherapy to RT in high-risk EC in addition to the PFS benefit demonstrated in the initial analysis.)

•Matei D, Filiaci V, Randall ME, et al. Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. N Engl J Med. 2019;380(24):2317–2326. https://doi.org/10.1056/NEJMoa1813181. (Trial comparing chemotherapy in high-risk EC as a control group to chemotherapy with the addition of chemoradiation, demonstrating no improvement in primary outcome of PFS in the experimental group.)

Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 1982;6(2):93–108. https://doi.org/10.1097/00000478-198203000-00002.

Article  CAS  PubMed  Google Scholar 

••Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. J Clin Oncol. 2018;36(20):2044–2051. https://doi.org/10.1200/JCO.2017.76.5966. (Trial demonstrating benefit of HER2 targeted therapy as an adjunct to primary treatment in prolonging progression-free survival in stage III and IV UPSC overexpressing HER2/neu.)

Abdulfatah E, Sakr S, Thomas S, et al. Clear cell carcinoma of the endometrium: evaluation of prognostic parameters in a multi-institutional cohort of 165 cases. Int J Gynecol Cancer. 2017;27(8):1714–21. https://doi.org/10.1097/IGC.0000000000001050.

Article  PubMed  PubMed Central  Google Scholar 

Matsuzaki S, Klar M, Matsuzaki S, Roman LD, Sood AK, Matsuo K. Uterine carcinosarcoma: contemporary clinical summary, molecular updates, and future research opportunity. Gynecol Oncol. 2021;160(2):586–601. https://doi.org/10.1016/j.ygyno.2020.10.043.

Article  CAS  PubMed  Google Scholar 

Toboni MD, Crane EK, Brown J, et al. Uterine carcinosarcomas: from pathology to practice. Gynecol Oncol. 2021;162(1):235–41. https://doi.org/10.1016/j.ygyno.2021.05.003.

Article  CAS  PubMed  Google Scholar 

Mbatani N, Olawaiye AB, Prat J. Uterine sarcomas. Int J Gynecol Obstet. 2018;143(S2):51–8. https://doi.org/10.1002/ijgo.12613.

Article  Google Scholar 

Levine DA. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73. https://doi.org/10.1038/nature12113.

Article  CAS  PubMed  PubMed Central  Google Scholar 

León-Castillo A, Gilvazquez E, Nout R, et al. Clinicopathological and molecular characterisation of ‘multiple-classifier’ endometrial carcinomas. J Pathol. 2020;250(3):312–22. https://doi.org/10.1002/path.5373.

Article  CAS  PubMed  PubMed Central  Google Scholar 

••León-Castillo A, de Boer SM, Powell ME, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J Clin Oncol. 2020;38(29):3388–3397. https://doi.org/10.1200/JCO.20.00549. (Using molecular classification data from PORTEC-3, this paper demonstrated strong prognostic association with molecular subclass in high risk EC, opening the door to further areas of risk-stratification when considering adjuvant treatment.)